Specific deletion of autoreactive T cells by adenovirus-transfected, Fas ligand-producing antigen-presenting cells

Immunologic Research

Volumn 26, Issue 1-3, 2002, Pages 235-246

  Zhang, H G ^a,b   Mountz, J D ^a,b   Fleck, M ^c   Zhou, T ^a   Hsu, H C ^a  

^a University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Antigen presenting cells; Autoimmune disease; Fas ligand; Immune privilege; T cells

Indexed keywords

ANTIGEN; FAS ANTIGEN; FAS LIGAND;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; CHRONIC INFLAMMATION; GENE THERAPY; HOMEOSTASIS; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIALOADENITIS; SJOEGREN SYNDROME; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION;

ADENOVIRIDAE; ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD95; APOPTOSIS; AUTOIMMUNITY; FAS LIGAND PROTEIN; FEMALE; INFLAMMATION; MALE; MEMBRANE GLYCOPROTEINS; MICE; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTES; TRANSFECTION;

EID: 0036395912     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:26:1-3:235     Document Type: Article

References (53)

1. Ouallet J, Baumann N, Marie Y. Villarroya H. Fas system up-regulation in experimental autoimmune encephalomyelitis. J Neurol Sci 1999;170:96-104.
2. Garcia-Velasco JA, Arici A, Zreik T, Naftolin F, Mor G. Macrophage derived growth factors modulate Fas ligand expressions in cultured endometrial stromal cells: a role in endometriosis. Mol Hum Reprod 1999;5:642-650.
3. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992;356:314-317.
4. Wu J, Zhou T, He J, Mountz JD: Autoimmune disease in mice due to integration of an endogenous retrovirus in an apoptosis gene. J Exp Med 1993;178:461-468.
5. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagata S: Generalized lymphoproliferative disease in mice caused by a point mutation in the Fas ligand. Cell 1994;76:969-976.
6. Steinberg AD, Raveche ES, Laskin CA, Smith HR, Santoro T, Miller ML, Plotz PH: NIH conference: systemic lupus erythematosus: insights from animal models. Ann Intern Med 1984;100:714-727.
7. Cohen PL, Eisenberg RA: The lpr and gld genes in systemic auto-immunity: life and death in the Fas lane. Immunol Today 1992;13:427-428.
8. Matsumura R, Umemiya K, Kagami M, Tomioka H, Tanabe E, Sugiyama T, Sueishi M, Nakajima A, Azuma M, Okumura K, Sumida T: Glandular and extraglandular expression of the Fas-Fas ligand and apoptosis in patients with Sjögren's syndrome. Clin Exp Rheumatol 1998;16:561-568.
9. Ohlsson M, Skarstein K, Bolstad AI, Johannessen AC, Johnnson R: Fas-induced apoptosis is a rare event in Sjögren's syndrome. Lab Invest 2001;81:95-105.
10. Jabs DA, Lee B, Whittum-Hudson J, Prendergast RA: The role of Fas-Fas ligand-mediated apoptosis in autoimmune lacrimal gland disease in MRL/MpJ mice. Invest Ophthalmol Vis Sci 2001;42:399-401.
11. Wahlsten JL, Gitchell HL, Chan CC, Wiggert B, Caspi RR: Fas and Fas ligand expressed on cells of the immune system, not on the target tissue, control induction of experimental autoimmune uveitis. J Immunol 2000;165:5480-5486.
12. Bamberger AM, Schulte HM, Thuneke I, Erdmann I, Bamberger CM, Asa SL: Expression of the apoptosis-inducing Fas ligand (FasL) in human first and third trimester placenta and choriocarcinoma cells. J Clin Endocrinol Metab 1997;82:3173-3175.
13. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC: A role for CD95 ligand in preventing graft rejection. Nature 1995;377:630-632.
14. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270:1189-1192.
15. Hammer A, Blaschitz A, Daxbock C, Walcher W, Dohr G: Fas and Fas-ligand are expressed in the uteroplacental unit of first-trimester pregnancy. Am J Reprod Immunol 1999;41:41-51.
16. Uckan D, Steele A, Chery, Wang BY, Chamizo W, Koutsonikolis A, Gilbert-Barness E, Good RA: Trophoblasts express Fas ligand: a proposed mechanism for immune privilege in placenta and maternal invasion. Mol Hum Reprod 1997;3:655-662.
17. Moalem G, Monsonego A, Shani Y, Cohen IR, Schwartz M: Differential T cell response in central and peripheral nerve injury: connection with immune privilege. FASEB J 1999;13:1207-1217.
18. Saitoh A, Kawanabe T, Weidong H, Kayagaki N, Kawamura T, Yagita H, Okumura K, Shimada S: Selective upregulation of fibroblast Fas ligand expression, and prolongation of Fas/Fas ligand-mediated skin allograft survival, by retinoic acid: the skin as a retinoide-inducible immune privilege site. J Invest Dermatol 2000;115:154-161.
19. Fang SY, Yang BC: Overexpression of Fas-ligand in human nasal polyps. Ann Otol Rhinol Laryngol 2000;109:267-270.
20. Ichinose M, Masuoka J, Shiraishi T, Mineta T, Tabuchi K: Fas ligand expression and depletion of T-cell infiltration in astrocytic tumors. Brain Tumor Pathol 2001;18:37-42.
21. O'Connell J, Bennett MW, O'Sullivan GC, O'Callaghan J, Collins JK, Shanahan F: Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege. Clin Diagn Lab Immunol 1999;6:457-463.
22. O'Connell J, Bennett MW, Nally K, Houston A, O'Sullivan GC, Shanahan F: Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict. Ann NY Acad Sci 2000;910:178-192.
23. Ohshima K, Nakashima M, Sonoda K, Kikuchi M, Watanabe T: Expression of RCAS1 and FasL in human trophoblasts and uterine glands during pregnancy: the possible role in immune privilege. Clin Exp Immunol 2001;123:481-486.
24. Tsai ST, Fang SY, Jin YT, Su IJ, Yang BC: Analysis of the expression of Fas-L in nasopharyngeal carcinoma tissues. Oral Oncol 1999;35:421-424.
25. Shibakita M, Tachibana M, Dhar DK, Kotoh T, Kinugasa S, Kubota H, Masunaga R, Nagasue N: Prognostic significance of Fas and Fas ligand expressions in human esophogeal cancer. Clin Cancer Res 1999;5:2464-2469.
26. Bennett MW, O'Connell J, O'Sullivan GC, Roche D, Brade C, Kelly J, Collins JK, Shanahan F: Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. Gut 1999;44:156-162.
27. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, Green DR, Kratzke RA: Human lung carcinomas express Fas ligand. Cancer Res 1997;57:1007-1012.
28. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J: Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996;274:1363-1366.
29. Fleck M, Kern ER, Zhou T, Lang B, Mountz JD: Murine cytomegalovirus induces a Sjögren's syndrome-like disease in C57B1/6-1pr/1pr mice. Arthritis Rheum 1998;41:2175-2184.
30. Zhang HG, Su X, Liu D, Liu W, Yang P, Wang Z, Edwards CK, Bluethmann H, Mountz JD, Zhou T: Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells. J Immunol 1999;162:1423-1430.
31. Zhang HG, Bilbao G, Zhou T, Contreras JL, Gomez-Navarro J, Feng M, Saito I, Mountz JD, Curiel DT: Application of a Fas ligand encoding a recombinant adenovirus vector for prolongation of transgene expression. J Virol 1998;72:2483-2490.
32. Zhang HG, Fleck M, Kern ER, Liu D, Wang Y, Hsu HC, Yang P, Wang Z, Curiel DT, Zhou T, Mountz JD: Antigen presenting cells expressing Fas ligand down-modulate chronic inflammatory disease in Fas ligand-deficient mice. J Clin Invest 2000;105:813-821.
33. Zhang HG, Liu D, Heike Y, Yang P, Wang Z, Wang X, Curiel DT, Zhou T, Mountz JD: Induction of specific T-cell tolerance by adenovirus-transfected, Fas ligand-producing antigen presenting cells. Nat Biotechnol 1998;16:1045-1049.
34. Ogsawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S: Lethal effect of the anti-Fas antibody in mice. Nature 1993;364:806-809.
35. Fleck M, Zhang HG, Kern ER, Hsu HC, Muller-Ladner U, Mountz JD: Treatment of chronic sialadenitis in a murine model of Sjögren's syndrome by local fasL gene transfer. Arthritis Rheum 2001;44:964-973.
36. Hsu HC, Zhang HG, Song GG, Xie J, Liu D, Yang PA, Fleck M, Wintersherger W, Zhou T, Edwards CK 3rd, Mountz JD: Defective Fas ligand-mediated apoptosis predisposes to development of a chronic erosive arthritis subsequent to Mycoplasma pulmonis infection. Arthritis Rheum 2001;44:2146-2159.
37. Zhang H-G, Yang P, Xie J, Liu L, Liu D, Xiu L, Zhou T, Wang Y, Hsu H-C, Mountz JD: Depletion of collagen II-reactive T cells and blocking of B-cell activation prevents collagen II-induced arthritis in DBA/1j mice. J Immunol 2002;168:4164-4172.
38. Wang H, Marsters SA, Baker T, Chan B, Lee WP, Fu L, Tumas D, Yan M, Dixit VM, Ashkenazi A, Grewal IS: TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol 2001;2:632-637.
39. Yu G, Boone T, Delaney J, et al: APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol 2000;1:252-256.
40. Marsters SA, Yan M, Pitti RM, Haas PE, Dixit VM, Ashkenazi A: Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol 2000;10:785-788.
41. Matsuno K, Fujii H, Kotani M: Splenic marginal-zone macrophages and marginal metallophils in rats and mice. Cell Tissue Res 1986;246:263-269.
42. Seiler P, Aichele P, Odermatt B, Hengartner H, Zinkernagel RM, Schwendener RA: Crucial role of marginal zone macrophages and marginal zone metallophils in the clearance of lymphocytic choriomeningitis virus infection. Eur J Immunol 1997;27:2626-2633.
43. Harms G, Dijkstra CD, Hardonk MJ: Glycsyl receptors in macrophage subpopulations of rat spleen and lymph node: a comparative study using neoglycoproteins and monoclonal antibodies ED1, ED2 and ED3. Cell Tissue Res 1990;262:35-40.
44. Roscic-Mrkic B, Schwendener RA, Odermatt B, Zuniga A, Pavlovic J, Billeter MA, Cattaneo R: Roles of macrophages in measles virus infection of genetically modified mice. J Virol 2001;75:3343-3351.
45. Mach N, Gillessen S, Wilson SB, Sheehan C, Hihm M, Dranoff G: Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor of Flt3-ligand. Cancer Res 2000;60:3239-3246.
46. Smathers PA, Santoro TJ, Chused TM, Reeves JP, Steinberg AD: Studies of lymphoproliferation in MRL-1pr/1pr mice. J Immunol 1984;133:1955-1961.
47. Dodd CH, Hsu HC, Chu WJ, Yang P, Zhang HG, Mountz JD Jr, Zinn K, Forder J, Josephson L, Weissleder R, Mountz JM, Mountz JD: Normal T-cell response and in vivo magnetic resonance imaging of T cells loaded with HIV transactivator-peptide-derived superparamagnetic nanoparticles. J Immunol Methods 2001;256:89-105.
48. Eloranta ML, Alm GV: Splenicmarginal metallophilic macrophages and marginal zone macrophages are the major interferon-alpha/beta producers in mice upon intravenous challenge with herpes simplex virus. Scand J Immunol 1999;49:391-394.
49. Su X, Cheng J, Liu W, Liu C, Wang Z, Yang P, Zhou T, Mountz JD: Autocrine and paracrine apoptosis are mediated by differential regulation of Fas ligand activity in two distinct Jurkat T cell populations. J Immunol 1998;160:5288-5293.
50. Halaas O, Vik R, Ashkenazi A, Espevik T: Lipopolysaccharide induces expression of APO2 ligand/TRAIL in human monocytes and macrophages. Scand J Immunol 2000;51:244-250.
51. Hoves S, Niller HH, Krause SW, Straub R, Gluck T, Mountz JD, Scholmerich J, Fleck M: Decreased T cell stimulatory capacity of monocyte-derived human macrophages following herpes simplex virus type 1 infection. Scand J Immunol 2001;54:93-99.
52. Yamagami S, Kawashima H, Tsuru T, Yamagami H, Kayagaki N, Yagita H, Okumura K, Gregerson DS: Role of Fas-Fas ligand interactions in the immunorejection of allogeneic mouse corneal transplants. Transplantation 1997;64:1107-1111.
53. Stuart PM, Griffith TS, Usui N, Pepose J, Yu X, Ferguson TA: CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest 1997;99:396-402. 235-246